In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device M&A Rebound Continues: With Ardian, Sadra Deals Show Appetite For Big, Early-Stage Acquisitions

Executive Summary

The year looks to be closing strong in terms of device M&A as the rebound we noted last month has continued, highlighted by the recent acquisitions of Ardian, with its novel percutaneous technology for hypertension (and perhaps other conditions), by Medtronic in what could turn out to be a billion dollar deal, and Boston Scientific's leap into the hot transcatheter valve space with its acquisition of Sadra Medical. At a time when acquirers and investors claim to be looking primarily for more mature, commercial-stage companies, these deals indicate that there remains a robust demand for truly innovative devices that address significant unmet needs and markets

Related Content

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q4 2010
Masterminds of Ardian: An Interview With Inventors Mark Gelfand and Howard Levin
Top Device Stories Of 2010: Waiting For The Other Shoes To Fall
In Medical Devices, Is "Good Enough" Good Enough?
In Medical Devices, Is "Good Enough" Good Enough?
Stryker And St. Jude Acquisitions Signal Year-end Uptick In Device M&A
At PCR, Valves Steal The Show, But DES Shine
Negative Innovation: Helping Reduce Health Care Technology Costs
Ardian: Succeeding Where Drugs Fail--Treating Hypertension in the Cath Lab
Boston Scientific Shuffles and Sells in Bid to Right Ship


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts